LianBio Rejects Acquisition Proposal from Concentra Biosciences, Focusing on Innovative Medicines for Asian Markets
Shanghai, China and Princeton, N.J. - LianBio (NASDAQ: LIAN), a leading biotechnology company committed to delivering groundbreaking medications to patients in China and other major Asian markets, has announced that its Board of Directors unanimously decided not to pursue the unsolicited proposal from Concentra Biosciences, LLC. The proposal entailed acquiring 100% of LianBio’s equity for $4.30 per share in cash, accompanied by a contingent value right giving the acquirer 80% of the net proceeds from any license or disposition of LianBio’s programs.
This resolute decision by LianBio’s Board underscores the company’s commitment to its mission of bringing innovative medicines to patients in Asia. It reflects the confidence that the Board has in LianBio’s potential to continue its successful growth trajectory independently.
Founded on the core principles of scientific excellence, strategic partnerships, and patient-centricity, LianBio has emerged as a key player in the biotechnology industry, particularly in China and other major Asian markets. The company has made significant strides in identifying, developing, and commercializing innovative therapies that address critical unmet medical needs.
LianBio’s unwavering dedication to advancing healthcare solutions is well-evidenced by its robust pipeline of promising drug programs. These programs, spanning multiple therapeutic areas, hold tremendous potential for transforming patients’ lives and enhancing the treatment landscape in Asia.
The decision not to pursue the acquisition proposal from Concentra Biosciences represents a vote of confidence in LianBio’s ability to capture the growing demand for advanced therapies in Asian markets. It also highlights the Board’s belief in the company’s unique value proposition, strategic vision, and long-term growth prospects.
While the proposal from Concentra Biosciences may have appeared lucrative on the surface, LianBio’s Board astutely evaluated the potential impact on the company’s strategic objectives, ongoing collaborations, and overall mission. By rejecting this proposal, LianBio aims to maintain its autonomy and retain complete control over its strategic decisions and partnerships, ensuring optimum opportunities for growth and innovation.
LianBio’s Board recognizes the significance of its role as a leading biotech company in Asia and the responsibility it bears towards patients, partners, and stakeholders. The decision to decline the acquisition proposal reflects its unwavering dedication to delivering superior healthcare solutions, supporting local innovation, and fostering collaborations that drive meaningful impact across the region.
Looking ahead, LianBio remains committed to accelerating the development and commercialization of transformative medicines for Asian patients, with a keen focus on addressing urgent medical needs and improving therapeutic outcomes. By nurturing strategic partnerships, driving scientific excellence, and operating with an unwavering patient-centric approach, LianBio is well-positioned to continue its remarkable journey of innovation and growth in the Asian biotech landscape.
Comments